Every 424B that EUDA Health Holdings Limited Warrant (EUDAW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow EUDAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EUDAW filings page.
Euda Health Holdings Limited reports that it has terminated its at-the-market equity offering program and the related At The Market Offering Agreement with Chardan Capital Markets, LLC. The program had previously allowed sales of ordinary shares with an aggregate offering price of up to $10.0 million, but this capacity had been reduced to zero and no ordinary shares were sold. All related prospectus supplements are also terminated as of the date of this supplement. The company’s ordinary shares trade on the NASDAQ Capital Market under the symbol EUDA, and the closing price was $15.30 on July 21, 2026.
EUDA Health Holdings filed a prospectus supplement to amend its prior ATM registration, reducing the maximum aggregate offering price to $10.0 million and suspending further sales under the ATM Agreement. The company states that no ordinary shares have been sold under the ATM Agreement as of the date of this Supplement. The company notified the manager on June 5, 2026 of its intent to terminate the ATM Agreement; the termination becomes effective 30 business days after that notice per the agreement. The supplement notes the Nasdaq closing price of the ordinary shares was $15.50 on June 11, 2026.
EUDA Health is registering 12,500,000 ordinary shares in a registered direct offering. The offering is being made pursuant to Securities Purchase Agreements dated February 24 and 25, 2026 and is being issued directly to accredited investors without a placement agent.
The company estimates net proceeds of approximately $3,692,000. As of the date of this Prospectus Supplement there were 37,807,491 Ordinary Shares outstanding; the company states there will be 50,307,491 Ordinary Shares issued and outstanding after this offering. The Ordinary Shares trade on Nasdaq under the symbol EUDA; the cited closing price on February 27, 2026 was $0.9747.
EUDA Health Holdings Limited has filed a 2026 prospectus supplement for its existing at-the-market equity program, allowing it to sell ordinary shares with an aggregate offering price of up to $10,000,000 through Chardan Capital Markets as sales agent. The company states that no ordinary shares have been sold under this Sales Agreement to date.
The supplement highlights business risks, including uncertainty around plans to work with third parties to establish a longevity clinic in Shenzhen, China, for which no binding agreements or approvals currently exist. It also notes uncertainty around launching an integrated digital health and rewards platform and the future use of QB coin utility cryptocurrency, which is still in development by a third party. EUDA cautions that failure of these initiatives could materially and adversely affect its business and results of operations.